| abstract |
Provided is a pharmaceutical composition used for the treatment of refractory heart tissue fibrosis heart disease associated with chronic heart failure. It consists of proteolytic enzyme inhibitors, thromboxane A2 biosynthesis enzyme inhibitors and antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents as active ingredients. A pharmaceutical composition (including these biodegradable polymer-encapsulated sustained-release preparations) used for the treatment of intractable cardiac tissue fibrosis associated with chronic heart failure, using at least one selected from the group. |